Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-04418948 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PF-04418948 30 mg | EXPERIMENTAL | - |
| PF-04418948 100 mg | EXPERIMENTAL | - |
| PF-04418948 300 mg | EXPERIMENTAL | - |
| PF-04418948 1000 mg | EXPERIMENTAL | - |
| PF-04418948 3000 mg | EXPERIMENTAL | - |
| PF-04418948 4500 mg | EXPERIMENTAL | - |
| PF-04418948 6000 mg | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PF-04418948 | DRUG | solution, 30 mg, single |
Inclusion Criteria: * Healthy male subjects between the ages of 18 and 55 years. * Body Mass Index (BMI) of 17.5 to 30.5 kg/m\^2; and a total body weight \>50 kg (110 lbs). Exclusion Criteria: * Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointest...
PF-04418948 is an investigational small molecule developed by Pfizer, Inc. It has been studied in a Phase 1 clinical trial in healthy adult male volunteers. The specific disease or condition it is intended to treat has not been disclosed, and it remains in early clinical development.
PF-04418948 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored the Phase 1 study of the compound conducted in Belgium. No partnership or licensing arrangement for PF-04418948 has been announced.
PF-04418948 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA. The only recorded trial was a completed Phase 1 study, and no active trials are currently listed for this compound.
PF-04418948 has been evaluated in one clinical trial, NCT01002963, titled A Study To Investigate The Safety And Toleration Of A Single Dose Of PF-04418948 In Healthy Volunteers. The Phase 1 trial enrolled 56 healthy male volunteers in Belgium, was randomized, double-blind, and controlled, and is now completed.
The Phase 1 trial of PF-04418948, NCT01002963, was a randomized, double-blind, controlled study of a single dose in healthy volunteers. It enrolled 56 male participants aged 18 years and older in Belgium. The trial assessed safety and toleration and has been completed.